A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS ® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Condition: Bioequivalence Interventions: Drug: Test Product; Drug: Reference Product Sponsors: Respirent Pharmaceuticals Co Ltd.; BECRO Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials